Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor Effect on Endothelial Function
NCT02261922Phase 4Unknown
- Sponsor
- Hôtel-Dieu de France
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by Hôtel-Dieu de France. Primary endpoint: Flow Mediated Dilation of the brachial artery at 8 days. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02261922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261922.